DOI: https://doi.org/10.30841/2307-5090.4.2019.195271

Аванафил – новая молекула для лечения эректильной дисфункции на рынке Украины

В. В. Спиридоненко

Аннотация


Представленный обзор современных литературных источников по аванафилу в терапии эректильной дисфункции и сопутствующих ей некоторых патологий мужской половой системы указывает на перспективность применения данного препарата у сексологических пациентов, учитывая его высокую эффективность и безопасность.

Ключевые слова


аванафил; аваналав; эректильная дисфункция; ингибиторы PDE-5

Полный текст:

PDF

Литература


Гурженко ЮМ., Спиридоненко ВВ. (2018) 20-й Конгрес Європейського товариства сексуальної медицини // Здоровье мужчины, № 1 (64), С. 13-17.

Спиридоненко ВВ. (2010) Эффективность экстракта якорцев стреляющихся при эректильной дисфункции у лиц с сахарным диабетом // Здоровье мужчины. № 2 (33). С. 3-6.

Горпинченко ИИ., Гурженко ЮН., Спиридоненко ВВ., Гурженко АЮ. (2012) Результаты применения экстракта якорцов стелющихся у мужчин с метаболическим синдромом, осложненным эректильной дисфункцией // Здоровье мужчины. № 3. С. 72-74.

Горпинченко И.И. (2002) Эректильная дисфункция: диагностика и современные методы лечения // Здоровье мужчины. № 1. С. 9-11.

Гурженко ЮМ. (2017) Клінічний досвід застосування препарату Зидена у терапії еректильної дисфункції // Здоровье мужчины, № 4 (63), С. 54-61.

Evans JD, Hill SR. (2015) A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient Prefer Adherence. Aug 12;9:1159-64.

Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, Damiano R, Montorsi F, Salonia A. (2016) Avanafil – a further step to tailoring patient needs and expectations. Expert Rev Clin Pharmacol. Sep;9(9):1171-81.

Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K. (2013) Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Ther Adv Urol. Feb;5(1):35-41.

Segal R, Burnett AL. (2012) Avanafil for the treatment of erectile dysfunction. Drugs Today (Barc). Jan;48(1):7-15.

Can NÖ. (2018) Development of Validated and Stability-Indicating LCDAD and LC-MS/MS Methods for Determination of Avanafil in Pharmaceutical Preparations and Identification of a Novel Degradation Product by LCMS-IT-TOF. Molecules. Jul 19;23(7).

Zurawin JL, Stewart CA, Anaissie JE, Yafi FA, Hellstrom WJ. (2016) Avanafil for the treatment of erectile dysfunction. Expert Rev Clin Pharmacol. Sep;9(9):1163-70.

Avanafil for erectile dysfunction. (2019) Aust Prescr. 2019 Jun;42(3):113-114.

Egui-Rojo MA, Moncada-Iribarren I, Carballido-Rodríguez J, Martínez-Salamanca JI. (2014) Avanafil for the treatment of erectile dysfunction. An updated review. Arch Esp Urol. Dec;67(10):839-47.

Della Camera PA, Tellini R, Cito G, Rastrelli G, Maggi M, Chini T, De Nunzio C, Altieri VM, Serni S, Gacci M, Natali A. (2019) Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nervesparing prostatectomy: A prospective multicentre study. Urologia. Aug 23:391560319867809.

Cui YS, Li N, Zong HT, Yan HL, Zhang Y. (2014) Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. May-Jun;16(3):472-7.

Corona G, Rastrelli G, Burri A, Jannini EA, Maggi M. (2016) The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf.;15(2):237-47.

Kyle JA, Brown DA, Hill JK. (2013) Avanafil for erectile dysfunction. Ann Pharmacother. Oct;47(10):1312-20.

Sanford M. (2013) Avanafil: a review of its use in patients with erectile dysfunction. Drugs Aging. 2013 Oct;30(10):853-62.

Gur S, Sikka SC, Pankey EA, Lasker GF, Chandra S, Kadowitz PJ, Hellstrom WJ. (2015) Effect of avanafil on rat and human corpus cavernosum. Andrologia. Oct;47(8):897-903.

Yilmaz D, Bayatli N, Un O, Kadowitz PJ, Sikka SC, Gur S. (2014) The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. Feb;83(2):508.e7-12.

Wang H, Yuan J, Hu X, Tao K, Liu J, Hu D. (2014) The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr. Med Res Opin. Aug;30(8):1565-71.

Berges R, Schremmer D, Limberg R. (2017) Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI. MMW Fortschr Med. Jun;159 (Suppl 5):16-21.

Burke RM, Evans JD. (2012) Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag.;8:517-23.

Katz EG, Tan RB, Rittenberg D, Hellstrom WJ. (2014) Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag. 2014 Aug 27;10:701-11.

Park HJ, Kim SW, Kim JJ, Lee SW, Paick JS, Ahn TY, Park K, Park JK, Park NC. (2017) A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction. J Korean Med Sci. Jun;32(6):1016-1023.

Mirone V, Fusco F, Parazzini F, Zucchi A. (2016) A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice. Arch Ital Urol Androl. Jul 4;88(2):128-32.

Avanafil (Stendra)-another PDE5 inhibitor for erectile dysfunction. (2014) Med Lett Drugs Ther. May 12;56(1442):37-8.

Limin M, Johnsen N, Hellstrom WJ. (2010) Avanafil, a new rapid-onset hosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. Nov;19(11):1427-37.

Di Luigi L, Sansone M, Sansone A, Ceci R, Duranti G, Borrione P, Crescioli C, Sgrò P, Sabatini S. (2017) Phosphodiesterase Type 5 Inhibitors, Sport and Doping. Curr Sports Med Rep. Nov/Dec;16(6):443-447.

Soliman KA, Ibrahim HK, Ghorab MM. (2016) Formulation of avanafil in a solid self-nanoemulsifying drug delivery system for enhanced oral delivery. Eur J Pharm Sci. Oct 10;93:447-55.

Soliman KA, Ibrahim HK, Ghorab MM. (2016) Effect of different polymers on avanafil-β-cyclodextrin inclusion complex: in vitro and in vivo evaluation. Int J Pharm. Oct 15;512(1):168-177.

Hellstrom WJ, Kaminetsky J, Belkoff LH, Goldstein I, Tursi JP, Uy J, Peterson CA, Bowden CH, Day WW. (2015) Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. J Urol. Aug;194(2):485-92.

Swearingen D, Nehra A, Morelos S, Peterson CA. (2013) Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. Feb 26;212-248.

Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, Trask BA, Day WW. (2012) Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc. Sep;87(9):843-52.

Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, Kobayashi T, Kojima K, Yee S, Yamada Y, Kikkawa K, Omori K. (2012) Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. Aug;188(2):668-74.

Dhruva A, Hamsavardhini VK, Kamatham S, Kataria A, Kumar A, Shanthi M, Peedicayil J. (2019) Avanafil Inhibits the Contractility of the Isolated Caprine Detrusor Muscle. Int J Appl Basic Med Res. Oct-Dec;9(4):231-235.




Copyright (c) 2019 Здоровье мужчины

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-5547 (Online), ISSN 2307-5090 (Print)